ICOTYDE (Icotrokinra): First Targeted Oral Peptide for Plaque Psoriasis — FDA Approved

On March 18, 2026, the U.S. Food and Drug Administration approved ICOTYDE (icotrokinra), a first-in-class oral interleukin-23 receptor (IL-23R) antagonist peptide developed by Johnson & Johnson. The approval covers moderate-to-severe plaque psoriasis in adults and pediatric patients aged 12 years and older weighing at least 40 kg who are candidates for systemic therapy or phototherapy.

Icotrokinra is a synthetic macrocyclic peptide consisting of 13 amino acids, cyclized via a disulfide bond between two modified cysteine residues. It incorporates both natural and noncanonical amino acids, and each residue is chemically modified to resist protease degradation in the gastrointestinal tract. Structurally, it represents a novel therapeutic class distinct from both small-molecule drugs and monoclonal antibodies.

The compound binds IL-23R with sub-10-picomolar affinity, making it one of the highest-affinity peptide-receptor interactions observed in an orally administered therapeutic. Its estimated terminal elimination half-life in humans ranges from 9 to 16 hours, supporting once-daily dosing.

Interleukin-23 is a heterodimeric cytokine composed of p19 and p40 subunits. It signals through a receptor complex consisting of IL-23R and IL-12 receptor beta 1 (IL-12RB1) on the surface of immune cells, particularly Th17 cells, gamma-delta T cells, and innate lymphoid cells. Activation of this receptor complex triggers the JAK2/TYK2-STAT3 signaling cascade, which drives the production of downstream pro-inflammatory cytokines including IL-17A, IL-17F, IL-22, and interferon-gamma (IFN-gamma).

In the pathophysiology of plaque psoriasis, the IL-23/IL-17 axis is considered the central inflammatory driver. Dysregulated IL-23 signaling leads to chronic activation of Th17 cells, resulting in excessive keratinocyte proliferation, epidermal thickening, and the characteristic erythematous, scaly plaques. Genetic studies have further validated IL-23R as a psoriasis susceptibility locus.

Icotrokinra binds directly to IL-23R, preventing the IL-23 heterodimer (p19/p40) from engaging the IL-23R/IL-12RB1 receptor complex. This blocks downstream STAT3 phosphorylation selectively without affecting IL-12-dependent STAT4 activation. This selectivity is pharmacologically significant because it preserves IL-12-mediated immune surveillance while specifically suppressing the IL-23-driven inflammatory cascade.

• Mechanism: Direct IL-23 receptor antagonism at sub-10 pM affinity
• Selectivity: Blocks IL-23/STAT3 signaling without affecting IL-12/STAT4 pathway
• Downstream effect: Suppression of IL-17A, IL-17F, IL-22, and IFN-gamma production
• Pathway specificity confirmed in human immune cell assays measuring STAT3 vs. STAT4 phosphorylation

The oral delivery of peptide therapeutics has historically been one of the greatest challenges in pharmaceutical science. Peptides are typically degraded by gastric acid and proteolytic enzymes in the GI tract, and their molecular size limits passive intestinal permeation. Icotrokinra overcomes these barriers through its macrocyclic architecture.

The 13-amino-acid cyclic structure provides several biophysical advantages. Cyclization through a disulfide bond between modified cysteine residues confers enhanced resistance to proteolytic enzymes in the stomach and intestines, improved stability across a wide pH range, and superior membrane permeability enabling absorption through the intestinal wall. Each amino acid in the sequence is chemically modified, contributing to resistance against protease degradation throughout the GI tract.

Pharmacokinetic studies in animal models demonstrated oral bioavailability of 0.1 to 0.3 percent without the use of any absorption enhancer or permeation-enhancing excipient. While this absolute bioavailability may appear low in traditional pharmacokinetic terms, the sub-picomolar binding affinity means that even minimal systemic exposure generates substantial pharmacodynamic activity. Following oral dosing in rats and monkeys, fecal excretion of unabsorbed drug was the primary elimination route, and metabolite levels were low (each below 2 percent of dose), with unchanged icotrokinra being the main circulating component.

The ICONIC clinical development program encompasses four Phase 3 studies — ICONIC-ADVANCE 1, ICONIC-ADVANCE 2, ICONIC-LEAD, and ICONIC-TOTAL — enrolling approximately 2,500 patients. This represents one of the most comprehensive clinical programs for a psoriasis therapeutic, simultaneously evaluating efficacy in adults and adolescents, high-impact anatomical sites (scalp and genital psoriasis), and head-to-head comparisons against an active oral comparator (deucravacitinib).

In the ICONIC-ADVANCE 1 and ICONIC-ADVANCE 2 trials, icotrokinra 200 mg once daily demonstrated superiority over both placebo and deucravacitinib at Week 16. Approximately 70 percent of patients achieved clear or almost clear skin (IGA 0/1), and 55 percent achieved PASI 90 response. At Week 16, IGA 0/1 rates were 68 percent versus 11 percent (ADVANCE 1) and 70 percent versus 9 percent (ADVANCE 2) for icotrokinra versus placebo. Adverse event rates for icotrokinra-treated patients were within 1.1 percent of placebo through Week 16.

Long-term 52-week data showed continued improvement. In the ICONIC-ADVANCE treatment arms, rates of completely clear skin (PASI 100) increased from 41 percent to 49 percent in ADVANCE 1 and from 33 percent to 48 percent in ADVANCE 2 between Weeks 24 and 52. Patients initially randomized to placebo who switched to icotrokinra at Week 16 achieved comparable clearance by Week 52 (50 percent in ADVANCE 1, 43 percent in ADVANCE 2).

The ICONIC-LEAD trial enrolled 684 participants and included adolescent patients. At Week 52, continuous-treatment patients maintained PASI 90 at 84 percent versus 21 percent in the withdrawal arm, and IGA 0/1 at 82 percent versus 23 percent. Among adolescents, 86 percent achieved PASI 90 at one year, with 92 percent maintaining this response from Week 24 to Week 52. Nearly 60 percent of adolescents achieved complete skin clearance (PASI 100) at Week 52.

• ADVANCE 1/2 Week 16: ~70% IGA 0/1, ~55% PASI 90 (vs. placebo and deucravacitinib)
• ADVANCE 1 Week 52: PASI 100 increased from 41% to 49%
• ADVANCE 2 Week 52: PASI 100 increased from 33% to 48%
• ICONIC-LEAD Week 52: 84% PASI 90 maintenance in continuous treatment
• Adolescents: 86% PASI 90, 57% PASI 100 at Week 52
• Adverse event rates within 1.1% of placebo through Week 16
• No new safety signals identified through Week 52

Prior to icotrokinra, all approved IL-23-targeting therapies were injectable monoclonal antibodies: guselkumab (Tremfya), risankizumab (Skyrizi), and tildrakizumab (Ilumya). These biologics target the p19 subunit of the IL-23 cytokine itself, whereas icotrokinra targets the IL-23 receptor on the cell surface. This receptor-level antagonism represents a mechanistically distinct approach.

The injectable IL-23 antibodies have demonstrated high efficacy, with PASI 90 rates typically ranging from 70 to 80 percent at primary endpoints. Icotrokinra PASI 90 rates of approximately 55 percent at Week 16 and over 84 percent at Week 52 in continuous treatment position it competitively within this class, particularly given the oral route of administration. The head-to-head superiority over deucravacitinib (an oral TYK2 inhibitor) at Week 16 further establishes its position among systemic oral therapies.

From a structural biology perspective, the comparison is notable. Monoclonal antibodies are large proteins (~150 kDa) requiring parenteral administration, cold-chain storage, and specialized manufacturing in bioreactors. Icotrokinra is a synthetic cyclic peptide (~1.5 kDa) manufactured through chemical synthesis, stored at room temperature, and delivered orally. This represents a roughly 100-fold reduction in molecular weight while maintaining target specificity and affinity comparable to biological therapeutics.

The approval of icotrokinra carries significant implications for the field of peptide science beyond its immediate therapeutic application. It demonstrates that macrocyclic peptides can achieve oral bioavailability through intrinsic structural properties alone, without reliance on permeation enhancers, absorption promoters, or specialized delivery devices.

The key design principles validated by icotrokinra include: macrocyclization via disulfide bonds for conformational rigidity, incorporation of noncanonical amino acids for protease resistance, chemical modification of each residue to optimize lipophilicity and membrane permeability, and sub-picomolar target affinity to ensure pharmacological activity despite low absolute oral bioavailability. These principles provide a framework for future oral peptide drug candidates targeting other receptor systems.

For the research peptide community, icotrokinra represents a proof-of-concept that cyclic peptide scaffolds can bridge the gap between small-molecule oral drugs and injectable biologics. The compound validates the concept of receptor antagonism via synthetic peptides at a level of affinity and selectivity previously achievable only with monoclonal antibodies. This may accelerate research into oral peptide approaches for other immune-mediated inflammatory conditions, metabolic diseases, and oncology targets.

• Validates oral delivery of macrocyclic peptides without absorption enhancers
• Demonstrates sub-picomolar receptor affinity in a synthetic 13-amino-acid scaffold
• Bridges the efficacy gap between small molecules and injectable biologics
• Establishes noncanonical amino acid incorporation as a viable strategy for GI stability
• Opens research avenues for oral peptide antagonists in other therapeutic areas

The global psoriasis therapeutics market exceeded USD 30 billion in 2025, dominated by injectable IL-23 and IL-17 biologics. ICOTYDE enters this landscape as a potential disruptor by combining biologic-level efficacy with the convenience of oral administration. Johnson & Johnson has positioned icotrokinra for first-line systemic therapy, targeting the significant population of psoriasis patients who avoid or delay treatment due to needle aversion or the logistical burden of injectable biologics.

The competitive positioning of ICOTYDE is strengthened by its head-to-head superiority data against deucravacitinib (Sotyktu), the only other approved oral systemic therapy targeting the IL-23/TYK2 pathway. With the ICONIC-TOTAL trial evaluating icotrokinra in scalp and genital psoriasis — anatomical sites with high disease burden and limited treatment options — Johnson & Johnson is building a comprehensive clinical evidence package that spans multiple patient subpopulations.

Beyond psoriasis, the oral peptide platform underlying icotrokinra has implications for Johnson & Johnson's broader immunology pipeline. The ability to deliver targeted receptor antagonism via an oral peptide could be extended to other immune-mediated inflammatory diseases where IL-23 plays a pathogenic role, including Crohn's disease, ulcerative colitis, and psoriatic arthritis. Clinical development in these indications is anticipated.

The FDA approval of ICOTYDE (icotrokinra) marks a milestone in both dermatology and peptide science. As the first targeted oral peptide to achieve regulatory approval for an immune-mediated inflammatory disease, it validates decades of research into macrocyclic peptide design, oral peptide delivery, and receptor-level antagonism using synthetic scaffolds.

The ICONIC clinical program demonstrated that a 13-amino-acid cyclic peptide, administered as a once-daily oral tablet, can achieve skin clearance rates that position it competitively with injectable monoclonal antibodies costing orders of magnitude more to manufacture. For the peptide research community, this approval opens a new chapter in the translation of synthetic peptide chemistry into clinically validated therapeutics.

• Read more: Pinnacle Medicines Raises $89M for Next-Generation Oral Peptides → https://www.chemverify.com/learn/pinnacle-medicines-raises-89m-oral-peptides
• Read more: Luna18: The Oral Peptide Achieving 47% Bioavailability — A Potential Game-Changer → https://www.chemverify.com/learn/luna18-oral-peptide-47-percent-bioavailability
• Read more: Orforglipron FDA Approval April 2026: First Oral GLP-1 Without Food Restrictions → https://www.chemverify.com/learn/orforglipron-fda-approval-april-2026
• Read more: Unnatural Products and Novartis: A $1.7 Billion Deal for Synthetic Macrocyclic Peptides → https://www.chemverify.com/learn/unnatural-products-novartis-1-7-billion-macrocyclic-peptides-deal